Potential for biotech in a turbulent financial climate

Report this content

The climate for financing in biotech so far in 2022 is in sharp contrast to the booming climate of 2021. This year, geopolitical tensions, soaring inflation and an expected downturn in business activity are some of the concerns. Now, interest rates are rising and stock markets are finding their lowest levels since the outbreak of the pandemic in 2020. What is the current situation in biotech financing? Are there any signs of a turnaround? To answer these questions US investment bank Locust Walk recently published a report mapping the biotech financial climate in Q3.

Read the full article at biostock.se:


This is a press release from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se/en/


Documents & Links

Quick facts

Potential for biotech in a turbulent financial climate
Tweet this